Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

New perspectives in the therapy of chronic hepatitis B.

Lampertico P, Liaw YF.

Gut. 2012 May;61 Suppl 1:i18-24. doi: 10.1136/gutjnl-2012-302085. Review. No abstract available.

PMID:
22504916
2.

[Efficacy and treatment strategy for drug resistances of nucleos(t)ide analogues for chronic hepatitis B].

Hosaka T, Suzuki F, Kumada H.

Nihon Shokakibyo Gakkai Zasshi. 2011 Feb;108(2):210-4. Japanese. No abstract available.

PMID:
21307624
3.

Proper antiviral therapy for hepatitis B virus-associated acute-on-chronic liver failure.

Liu T, Zhang C, Wang Y.

Hepatology. 2011 Aug;54(2):747-8. doi: 10.1002/hep.24266. Epub 2011 Jun 27. No abstract available.

PMID:
21360719
4.

Tenofovir plus entecavir as rescue therapy for multidrug-resistant chronic hepatitis B.

Scotto G, D'Addiego G, Giammario A, Campanale F, Fazio V.

Liver Int. 2012 Jan;32(1):171-2. doi: 10.1111/j.1478-3231.2011.02611.x. Epub 2011 Aug 11. No abstract available.

PMID:
22098064
5.

Chronic hepatitis B: update 2009.

Lok AS, McMahon BJ.

Hepatology. 2009 Sep;50(3):661-2. doi: 10.1002/hep.23190. No abstract available.

6.

Potency of tenofovir in chronic hepatitis B: mono or combination therapy?

Reijnders JG, Janssen HL.

J Hepatol. 2008 Mar;48(3):383-6. doi: 10.1016/j.jhep.2007.12.006. Epub 2007 Dec 31. No abstract available.

PMID:
18191272
7.

Analogs and fibrosis regression in hepatitis B.

Akarca US.

Gastroenterol Clin Biol. 2010 Aug-Sep;34(6-7):419. doi: 10.1016/j.gcb.2010.03.010. Epub 2010 May 7. No abstract available.

8.

Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss.

Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL.

J Infect Dis. 2011 Aug 1;204(3):415-8. doi: 10.1093/infdis/jir282.

PMID:
21742840
9.

Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir.

Jung YK, Kim JH, Lee YS, Lee HJ, Yoon E, Jung ES, Hong SK, Joo MK, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS.

J Clin Gastroenterol. 2010 Oct;44(9):653-7. doi: 10.1097/MCG.0b013e3181d52946.

PMID:
20216430
10.

Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.

Ala A, Dieterich DT.

AIDS Read. 2004 Mar;14(3):134-5. Review. No abstract available.

PMID:
15068001
11.

[The past, present and future treatment for chronic hepatitis B].

Okanoue T, Minami M.

Nihon Rinsho. 2011 May;69 Suppl 4:469-74. Review. Japanese. No abstract available.

PMID:
22096963
12.

Another drug in the armamentarium to combat hepatitis B virus in adolescents.

Rosenthal P.

Hepatology. 2012 Dec;56(6):2016-7. doi: 10.1002/hep.25901. No abstract available.

PMID:
22711604
13.

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

European Association For The Study Of The Liver.

J Hepatol. 2012 Jul;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010. Epub 2012 Mar 20. No abstract available. Erratum in: J Hepatol. 2013 Jan;58(1):201. Janssen, Harry [corrected to Janssen, Harry L A].

14.

[IFN therapy in children with chronic hepatitis B].

Inui A, Komatsu H, Umetsu S, Sogo T, Fujisawa T.

Nihon Rinsho. 2015 Dec;73 Suppl 9:685-91. Japanese. No abstract available.

PMID:
26846022
15.

[Genetic factors in HLA-DP associated with pathology, therapeutic outcome, and prognosis of chronic hepatitis B].

Ochi H, Miki D, Chayama K.

Nihon Rinsho. 2015 Dec;73 Suppl 9:439-42. Japanese. No abstract available.

PMID:
26845974
16.

[Optimized strategy: new concept in antiviral therapy for chronic hepatitis B].

Yu-ming W, Cheng L.

Zhonghua Gan Zang Bing Za Zhi. 2012 Feb;20(2):82-5. doi: 10.3760/cma.j.issn.1007-3418.2012.02.002. Chinese. No abstract available.

PMID:
22586729
17.

Hepatitis B virus in children: More therapeutic options-but unknown and known unknowns still present.

Hadžić N, Bansal S.

Hepatology. 2016 Feb;63(2):360-2. doi: 10.1002/hep.28154. Epub 2015 Dec 8. No abstract available.

PMID:
26361247
18.

Reply to Liao et al.

Seto WK, Wong DK, Lai CL, Yuen MF.

Clin Infect Dis. 2013 Aug;57(4):622. doi: 10.1093/cid/cit295. Epub 2013 May 3. No abstract available.

PMID:
23645853
19.

How can the IL28B polymorphisms with linkage disequilibrium affect the natural course of hepatitis B inversely?

Keshvari M, Alavian SM, Sharafi H.

Liver Int. 2014 Aug;34(7):1127. doi: 10.1111/liv.12515. Epub 2014 Mar 24. No abstract available.

PMID:
24576012

Supplemental Content

Support Center